Project: A novel targeted treatment against ovarian cancer

Acronym	nOVAB (Reference Number: 113292)
Duration	01/10/2019 - 03/10/2022
Project Topic	We have discovered a specific epitope of a monoclonal antibody (mAb) that blocks a novel tumour cell-specific target, leading to cell death and reduced tumour growth via a novel cancer pathway. The nOVAB consortium aims to develop a mAb against the novel target into a treatment for solid tumours. Positioning of the mAb ultimately would be applicable in non-responders to immunotherapy. nOVAB’s focus on ovarian cancer is the first of solid tumours given there are few therapies available.
Network	Eurostars 2
Call	Eurostars Cut–off 11

Project partner

Number	Name	Role	Country
1	Temple Therapeutics	Coordinator	Netherlands
2	InSphero AG	Partner	Switzerland
3	Xenopat SL	Partner	Spain
4	Sahlgrenska Cancer Center at The Sahlgrenska Academy at the University of Gothenburg	Partner	Sweden